Physician profile
Gary Grad
NPI 1629039227
$120,865.10
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $4,853 · 2021: $1,617 · 2022: $2,532 · 2023: $110 · 2024: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $57,975.48 | 2019-2024 | Monjuvi |
| Genentech USA, INC. | $26,316.12 | 2019-2024 | Columvi, Polivy, Lunsumio |
| Janssen Biotech, INC. | $18,505.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $9,003.71 | 2019-2024 | Opdivo |
| Janssen Scientific Affairs, LLC | $4,040.00 | 2020 | |
| Celgene Corporation | $1,844.72 | 2019-2022 | |
| Intrinsiq Specialty Solutions, INC. | $1,500.00 | 2021 | |
| Merck Sharp & Dohme LLC | $280.05 | 2019-2022 | |
| Amgen INC. | $155.88 | 2019-2022 | |
| Abbvie INC. | $142.35 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $118.91 | 2019-2024 | Calquence |
| Pfizer INC. | $104.44 | 2019-2020 | |
| Genzyme Corporation | $80.07 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $67.24 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $66.59 | 2019-2023 | Imbruvica |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Grad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.